Sanofi-Aventis to acquire Symbion Consumer
This article was originally published in Scrip
Sanofi-Aventisis to acquire Symbion Consumer, a manufacturer and distributor of nutraceuticals and OTC vitamins and supplements in Australia and New Zealand, from Primary Health Care for A$560 million ($546 million). Symbion Consumer, which is a unit of Symbion Health, had sales of A$190 million last year and Sanofi-Aventis expects to complete the acquisition on August 31st. The acquisition should offer a platform for Sanofi-Aventis to launch a neutraceutical offering throughout the Asia/Pacific region, the company said. The sale of the consumer business will allow Primary to integrate itself further with the rest of Symbion Health, which it acquired in February for A$4.10 per share after nearly a year and a half-long bidding war between itself andHealthscope, Dr Edmund Bateman, Primary's managing director, said.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.